Insights into binding modes of tumstatin peptide T7 with the active site of α vβ 3 integrin

Molecular Simulation

Volumn 38, Issue 6, 2012, Pages 498-508

  Zan, Jinhang ^a   He, Xin ^a   Long, Wei ^a   Liu, Peixun ^a  

^a INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

v 3 integrin; docking; MD simulation; MM GBSA; T7 peptide

Indexed keywords

ACTIVE SITE; ANGIOGENESIS; BINDING MECHANISMS; BINDING MODES; INTEGRINS; INTERACTION SITE; MD SIMULATION; MM/GBSA; MOLECULAR DYNAMICS SIMULATIONS; STRUCTURE-BASED DRUG DESIGN; TUMOUR CELLS;

BINDING ENERGY; BINDING SITES; DOCKING; DRUG INTERACTIONS; MANGANESE; MANGANESE COMPOUNDS; MOLECULAR DYNAMICS;

PEPTIDES;

EID: 84859173444     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927022.2011.649428     Document Type: Article

References (43)

1. Y. Maeshima, P.C.A. Torre, K.A. Holthaus, J.A. Grunkemeyer, M.B. Ericksen, H. Hopfer, Y.W. Xiao, I.E. Stillman, and R. Kalluri, Distinct antitumor properties of a type IV collagen domain derived from basement membrane, J. Biol. Chem. 275 (2000), pp. 21340-21348.
2. E. Petitelerc, A. Boutaud, A. Prestayko, J.S. Xu, Y. Sado, Y. Ninomiya, M.P. Sarras, B.G. Hudson, and P.C. Brooks, New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo, J. Biol. Chem. 275 (2000), pp. 8051-8061.
3. Y. Maeshima, P.C. Colorado, and R. Kalluri, Two RGD-independent alpha v beta3 integrin binding sites on tumstatin regulate distinct anti-Tumor properties, J. Biol. Chem. 275 (2000), pp. 23745-23750.
4. Y. Maeshima, M. Manffredi, C. Reimer, K.A. Holthaus, H. Hopfer, B.R. Chandamuri, S. Kharbanda, and R. Kalluri, Identification of the anti-Angiogenic site within vascular basement membrane-derived tumstatin, J. Biol. Chem. 276 (2001), pp. 15240-15248.
5. Y. Maeshima, A. Sudhakar, J.C. Lively, K. Ueki, S. Kharbanda, C.R. Kahn, N. Sonenberg, R.O. Hynes, and R. Kalluri, Tumstatin, an endothelial cell-specific inhibitor of protein synthesis, Science 295 (2002), pp. 140-143.
6. Y. Maeshima, U.L. Yerramalla, M. Dhanabal, M. Dhanabal, K.A. Holthaus, S. Barbashov, S. Kharbanda, C. Reimer, M. Manfredi, W.M. Dickerson, and R. Kalluri, Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis, J. Biol. Chem. 276 (2001), pp. 31959-31968.
7. A. Sudhakar, H. Sugimoto, C. Yang, J. Lively, M. Zeisberg, and R. Kalluri, Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins, PNAS 100 (2003), pp. 4766-4771.
8. T.A. Shahan, Z. Ziaie, S. Pasco, A. Fawzi, G. Bellon, J.C. Monboisse, and N.A. Kefalides, Identification of CD47/ integrin-Associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells, Cancer Res. 59 (1999), pp. 4584-4590.
9. Y. Fujii, D. Okuda, Z. Fujimoto, K. Horii, T. Morita, and H. Mizuno, Crystal structure of trimestatin, a disintegrin containing a cell adhesion recognition motif RGD, J. Mol. Biol. 332 (2003), pp. 1115-1122.
10. 3-vitronectin association by a Ser-Asp-Val sequence through an Arg-Gly-Asp-binding site of the integrin, Proteomics 10 (2010), pp. 72-80.
11. P. McQuade and L.C. Knlght, Radiopharmaceuticals for targeting the angiogenesis marker alpha(v)beta(3), Q. J. Nucl. Med. 47 (2003), pp. 209-220.
12. Chemical Computing Group, Inc. CCG, Montreal, Canada, 2008.
13. B. Hess, C. Kutzner, D.V.D. Spoel, and E. Lindahl, GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation, J. Chem. Theory Comput. 4 (2008), pp. 435-447.
14. H.J.C. Berendsen, D.V. Spoel, and R.V. Drunen, GROMACS: A message-passing parallel molecular dynamics implementation, Comput. Phys. Commun. 91 (1995), pp. 43-56.
15. X. Daura, A.E. Mark, and W.F. van Gunsteren, Parametrization of aliphatic CHn united atoms of GROMOS96 force field, J. Comput. Chem. 19 (1998), pp. 535-547.
16. H.J.C. Berendsen, J.P.M. Postma, W.F. Gunsteren, and J. Hermans, Interaction models for water in relation to protein hydration, in Intermolecular Forces, B. Pullman, ed., Reidel Publ., Dordrecht, 1981, pp. 331-342.
17. T. Darden, D. York, and L. Pedersen, Particle mesh Ewald: An N* log (N) method for computing Ewald sums, J. Chem. Phys. 98 (1993), pp. 10089-10092.
18. J.P. Xiong, T. Stehle, R. Zhang, A. Joachimiak, M. Frech, S.L. Goodman, and M.A. Arnaout, Crystal structure of the extracellular segment of integrin alpha V beta3 in complex with an Arg-Gly-Asp ligand, Science 296 (2002), pp. 151-155.
19. D.A. Case, T.A. Darden, T.E. Cheatham, C.L. Simmerling, J. Wang, R.E. Duke, R.E. Duke, R. Luo, M. Crowley, R.C. Walker, W. Zhang, K.M. Merz, B. Wang, S. Hayik, A. Roitberg, G. Seabra, I. Kolossváry, K.F. Wong, F. Paesani, J. Vanicek, X. Wu, S.R. Brozell, T. Steinbrecher, H. Gohlke, L. Yang, C. Tan, J. Mongan, V. Hornak, G. Cui, D.H. Mathews, M.G. Seetin, C. Sagui, V. Babin, P.A. Kollman, AMBER 10, University of California, San Francisco, CA, 2008.
20. J.M. Wang, P. Cieplak, and P.A. Kollman, How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules, J. Comput. Chem. 21 (2000), pp. 1049-1074.
21. W.L. Jorgensen, J. Chandrasekhar, and J.D. Madura, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79 (1983), pp. 926-935.
22. J.P. Ryckaert, G. Ciccotti, and H.J.C. Berendsen, Numerical integration of the Cartesian equation of motion of a system with constraints: Molecular dynamics of n-Alkanes, J. Comput. Phys. 23 (1977), pp. 327-341.
23. J. Srinivasan, J. Miller, P.A. Kollman, and D.A. Case, Continuum solvent studies of the stability of RNA hairpin loops and helices, J. Biomol. Struct. Dyn. 16 (1998), pp. 671-682.
24. P.A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T.S. Lee, Y. Dong, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D.A. Case, and T.E. Chaetham, Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models, Acc. Chem. Res. 33 (2002), pp. 889-897.
25. A. Onufriev, D. Bashford, and D.A. Case, Modification of the generalized Born model suitable for macromolecules, J. Phys. Chem. B 104 (2000), pp. 3712-3720.
26. J. Weiser, P.S. Shenkin, and W.C. Still, Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO), J. Comput. Chem. 20 (1999), pp. 217-230.
27. S. Scheiner, Contributions of NH ⋯ O and CH ⋯ O hydrogen bonds to the stability of beta-sheets in proteins, J. Phys. Chem. B 110 (2006), pp. 18670-18679.
28. I. Daidone, M.B. Ulmschneider, A.D. Nola, A. Amadei, and J.C. Smith, Dehydration-driven solvent exposure of hydrophobic surfaces as a driven force in peptide folding, PNAS 104 (2007), pp. 15230-15235.
29. C.X. Wang, Y.Y. Shi, F. Zhou, and L. Wang, Thermodynamic integration calculations of binding free energy difference for Gly-169 mutation in subtilisin BPN, Proteins 15 (1993), pp. 5-9.
30. M. Michishita, V. Videm, and M.A. Arnaout, A novel divalent cation-binding site in the A domain of the beta 2 integrin CR3 (CD11b/CD18) is essential for ligand binding, Cell 72 (1993), pp. 857-867.
31. J.O. Lee, P. Rieu, M.A. Arnaout, and R. Liddington, Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18), Cell 80 (1995), pp. 631-638.
32. M.J. Humphries, Integrin structure, Biochem. Soc. Trans. 4 (2000), pp. 311-315.
33. I. Dransfield, C. Cabanas, A. Craig, and N. Hogg, Divalent cation regulation of the function of the leukocyte integrin LFA-1, J. Cell. Biol. 116 (1992), pp. 219-226.
34. J. Gailit and E. Ruoslahti, Regulation of the fibronectin receptor affinity by divalent cations, J. Biol. Chem. 263 (1988), pp. 12927-12932.
35. D. Fass, S. Blacklow, and P.S. Kim, Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module, Nature 388 (1997), pp. 691-693.
36. J.P. Xiong, T. Stehle, B. Diefenbach, R.G. Zhang, R. Dunker, D.L. Scot, A. Joachimiak, S.L. Goodman, and M.A. Arnaout, Crystal structure of the extracellular segment of integrin alpha Vbeta3, Science 294 (2001), pp. 339-345.
37. M.A. Dechantsreiter, E. Planker, B. Matha, E. Lohof, G. Hölzemann, A. Jonczyk, S.L. Goodman, and H. Kessler, N-methylated cyclic RGD peptides as highly active and selective alpha Vbeta3 integrin antagonists, J. Med. Chem. 42 (1999), pp. 3033-3040.
38. R. Haubner, R. Gratias, B. Diefenbach, S.L. Goodman, A. Jonczyk, and H. Kessler, Structural and functional aspects of RGDcontaining cyclic pentapeptides as highly potent and selective integrin alpha Vbeta3 antagonists, J. Am. Chem. Soc. 118 (1996), pp. 7461-7472.
39. E. Lohof, E. Planker, C. Mang, F. Burkhart, M.A. Dechantsreiter, R. Haubner, H.J. Wester, M. Schwaiger, G. Holzemann, S.L. Goodman, and H. Kessler, Carbohydrate derivatives for use in drug design: Cyclic alpha(v)-selective RGD peptides, Angew. Chem. Int. Ed. 39 (2000), pp. 2761-2764.
40. K.E. Gottschalk and H. Kessler, The structures of integrins and integrin-ligand complexes: Implications for drug design and signal transduction, Chem. Int. Ed. 41 (2002), pp. 3767-3774.
41. L. Marinelli, A. Lavecchia, K.E. Gottschalk, E. Novellino, and H. Kessler, Docking studies on alpha Vbeta3 integrin ligands: Pharmacophore refinement and implications for drug design, J. Med. Chem. 46 (2003), pp. 4393-4404.
42. B.P. Feuston, J.C. Culberson, M.E. Duggan, G.D. Hartman, C.T. Leu, and S.B. Rodan, Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin, J. Med. Chem. 45 (2002), pp. 5640-5648.
43. H.P. Eikesdal, H. Sugimoto, G. Birrane, Y. Maeshima, V.G. Cooke, M. Kieran, and R. Kalluri, Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity, PNAS 105 (2008), pp. 15040-15045.